BFM
EWTX icon

Boothbay Fund Management’s Edgewise Therapeutics EWTX Stock Holding History

Boothbay Fund Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,700
Closed -$174K – 2079
2025
Q3 		$174K Buy
+10,700
New +$152K ﹤0.01% 1670

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Boothbay Fund Management's EWTX Position: Q2 2025 in Review

Boothbay Fund Management sold out of Edgewise Therapeutics (EWTX) in Q2 2025, closing a stake of 85,214 shares — an estimated $1.87M sold.

Boothbay Fund Management first reported a position in EWTX in Q3 2022 and held it in 3 quarters. The position peaked at $1.87M in Q1 2025. 178 funds tracked by Wall St. Rank hold EWTX as of Q2 2025.

  • Boothbay Fund Management reported no remaining Edgewise Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 85,214 Edgewise Therapeutics shares in Q2 2025, an estimated $1.87M.
  • Boothbay Fund Management first reported a position in Edgewise Therapeutics in Q3 2022 and held it in 3 quarters.
  • Boothbay Fund Management's Edgewise Therapeutics position peaked at $1.87M in Q1 2025.
  • 178 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.